RxDoctor Payments Data

Mary Runkel

Nurse Practitioner · Des Moines, IANPI 1700868486

Payments from drug & device makers

$1,266in general payments, 2019–2025

Across 38 payments — averaging $33.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$614
  • AstraZeneca$262
  • Lilly USA, LLC$122
  • Philips North America LLC$71
  • AbbVie$43
  • Abiomed$42
  • plus $112 from 5 others

What the payments were for

  • Food & beverage$1,25299%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,266 in reported general payments places this provider in the 85th percentile of 1,346 nurse practitioner providers in Iowa.

See all nurse practitioner providers in Iowa

Medicare billing

Part B allowed, 2024
$30,969
Medicare patients
292
Services billed
747

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan561$595,760
EliquisApixaban311$291,265
JardianceEmpagliflozin318$285,587
VyndamaxTafamidis12$268,144
FarxigaDapagliflozin Propanediol206$166,504
XareltoRivaroxaban65$58,218
Bumetanide330$13,131
BrilintaTicagrelor17$12,419
Torsemide309$6,505
Metoprolol Succinate594$5,827
Eplerenone72$3,954
Spironolactone796$3,465
Potassium Chloride221$3,397
Dabigatran EtexilateDabigatran Etexilate Mesylate19$3,092
Bisoprolol Fumarate95$2,865

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$23$595,760561 claims
PfizerEliquis, Vyndamax$26$559,409323 claims
AstraZenecaFarxiga, Brilinta$262$178,923223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,346 nurse practitioner providers in Iowa.

Other nurse practitioner in Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →